98%
921
2 minutes
20
Rationale: Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease, and development of novel therapeutics requires an understanding of pathophysiologic phenotypes.
Objectives: The purpose of the Airways Disease Endotyping for Personalized Therapeutics (ADEPT) study was to correlate clinical features and biomarkers with molecular characteristics in a well-profiled COPD cohort.
Methods: A total of 67 COPD subjects (forced expiratory volume in the first second of expiration [FEV]: 45%-80% predicted) and 63 healthy smoking and nonsmoking controls underwent multiple assessments including patient questionnaires, lung function, and clinical biomarkers including fractional exhaled nitric oxide (FENO), induced sputum, and blood.
Measurements And Main Results: The impact of inhaled corticosteroids (ICSs), and to a lesser extent current smoking, was more associated with symptom control, exacerbation rates, and clinical biomarkers, than severity by FEV. The ICS-treated smoking subjects were most symptomatic, with significantly elevated scores on patient-reported outcomes and more annual exacerbations ( < .05). Inhaled corticosteroid users had greater airflow obstruction and air trapping compared with non-ICS users, regardless of smoking status. Smoking, regardless of ICS use, was associated with significantly lower FENO ( < .05). Smoking, in non-ICS users, was associated with an elevated proportion of sputum neutrophils and reduced sputum macrophages. Increased serum C-reactive protein was observed in smokers but not in ICS and nonsmoking ICS users ( < .05). In contrast, only air trapping and neutrophilic inflammation increased with severity, defined by postbronchodilator FEV.
Conclusions: Compared with COPD severity by FEV, ICS use and current smoking were better determinants of clinical characteristics and biomarkers. Use of the ADEPT COPD data promises to prove useful in defining biological phenotypes to facilitate personalized therapeutic approaches.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5593220 | PMC |
http://dx.doi.org/10.1177/1177271917730306 | DOI Listing |
Neuroimage
September 2025
UMRS1158 Neurophysiologie Respiratoire Expérimentale et Clinique, INSERM, Sorbonne Université, Paris, France; Assistance Publique-Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Département R3S, Paris, France. Electronic address:
Background: Neural respiratory drive (NRD) is a clinically relevant biomarker in patients with chronic obstructive pulmonary disease (COPD). However, its analysis is challenging due to several technical considerations, including the need to obtain a stable recording over a short time period. However, a short recording duration may be inadequate to comprehensively record clinically relevant information, particularly during sleep, because NRD varies across sleep stages and over time.
View Article and Find Full Text PDFPharmacol Ther
September 2025
Department of Molecular Pharmacology, University of Groningen, Groningen, the Netherlands; Groningen Research Institute for Asthma and COPD, GRIAC, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. Electronic address:
Air pollution is a significant public health issue that impacts lung health, particularly in vulnerable populations such as children, the elderly, and individuals with pre-existing respiratory conditions. Both natural and anthropogenic sources of air pollution give rise to a variety of toxic compounds, including particulate matter (PM), ozone (O₃), sulfur dioxide (SO₂), nitrogen dioxide (NO₂), carbon monoxide (CO), and polycyclic aromatic hydrocarbons (PAHs). Exposure to these pollutants is strongly associated with the development and exacerbation of respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD), lung cancer, and idiopathic pulmonary fibrosis (IPF).
View Article and Find Full Text PDFMol Genet Genomics
September 2025
Department of Biochemistry, Bahauddin Zakariya University, Multan, Multan, 66000, Punjab, Pakistan.
Moraxella catarrhalis is a Gram-negative diplococcus bacterium and a common respiratory pathogen, implicated in 15-20% of otitis media (OM) cases in children and chronic obstructive pulmonary disease (COPD) in adults. The rise of drug-resistant Moraxella catarrhalis has highlighted the urgent need for the potent vaccine strategies to reduce its clinical burden. Despite a mortality rate of 13%, there is no FDA-approved vaccine for this pathogen.
View Article and Find Full Text PDFJ Am Pharm Assoc (2003)
September 2025
WVU Medicine - WVU Hospitals; Morgantown, WV; West Virginia University School of Pharmacy; Morgantown, WV.
Background: Long-acting muscarinic antagonist (LAMA) and long-acting beta agonist (LABA) combination maintenance therapy is recommended for patients with Group B chronic obstructive pulmonary disease (COPD) in the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines. Exposure to inhaled corticosteroids (ICS) in these patients may increase adverse effects without adding clinical benefit. Inpatient formulary limitations may facilitate unnecessary exposure to ICS and ICS-associated adverse events while hindering the use of optimal LAMA/LABA inhaler therapy in Group B COPD patients.
View Article and Find Full Text PDFEndoscopy
December 2025
Department of Gastroenterology and Hepatology, Yokohama City University School of Medicine Graduate School of Medicine, Yokohama, Japan.